Reata Pharmaceuticals, Inc. Class A Common Stock

RETA

Market cap $6.57B

NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.

NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.

NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.

NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.

NEW YORK, NY / ACCESSWIRE / April 4, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.

NEW YORK, NY / ACCESSWIRE / April 2, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.

NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.

NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.

NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ: RETA). The settlement provides for a fund of $45,000,000 to benefit class members.

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ:RETA). The settlement provides for a fund of $45,000,000 to benefit class members.